Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells
Open Access
- 20 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 14 (11) , 1529-1538
- https://doi.org/10.1093/hmg/ddi161
Abstract
Mutations in fibroblast growth factor receptor 3 (FGFR3) cause the most common genetic form of short-limbed dwarfism, achondroplasia (ACH), as well as neonatal lethal forms, thanatophoric dysplasia (TD) I and II. The causative mutations induce graded levels of constitutive activation of the receptor that correspond to the severity of the disorder, resulting in premature entry into hypertrophic differentiation and reduced proliferation of chondrocytes in developing cartilage. Although FGFR3 promotes growth in most tissues, it is a negative regulator of endochondral bone growth. Several signaling pathways have been implicated in these skeletal disorders including the Ras/MEK/ERK pathway and the JAK/STAT, the latter in the most severe phenotypes, however their functional relevance remains incompletely understood. Using PC12 cell lines stably expressing inducible mutant receptors containing the TDII mutation, K650E, sustained activation of ERK1/2 and activation of STAT1 and STAT3, but not STAT5, is observed in the absence of ligand. This activation leads to neurite outgrowth, a phenotypic readout of constitutive receptor activity, and sustained ERK1/2 activity is required for this ligand-independent differentiation. To assess the functional relevance of STAT activation induced by the mutant receptor, STATs were specifically downregulated using RNA-interference. Silencing of STAT1 or 3 independently or in combination had no significant effect on ligand-independent neurite outgrowth, ERK1/2 activation or p21WAF1/CIP1 protein levels. These results support a model in which sustained activation of ERK1/2 is a key regulator of the increased transition to hypertrophic differentiation of the growth plate, whereas activation of STATs 1 and 3 is not required.Keywords
This publication has 61 references indexed in Scilit:
- Fibroblast growth factors share binding sites in heparan sulphateBiochemical Journal, 2005
- Involvement of Down-Regulation of Cdk2 Activity in Hepatocyte Growth Factor-Induced Cell Cycle Arrest at G1 in the Human Hepatocellular Carcinoma Cell Line HepG2The Journal of Biochemistry, 2004
- FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cellsExperimental Cell Research, 2004
- The Cytoplasmic Tyrosine Kinase Pyk2 as a Novel Effector of Fibroblast Growth Factor Receptor 3 ActivationJournal of Biological Chemistry, 2004
- Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -β-catenin-independent signaling pathwayExperimental Cell Research, 2004
- Activation of the ERK1/2 and p38 Mitogen-activated Protein Kinase Pathways Mediates Fibroblast Growth Factor-induced Growth Arrest of ChondrocytesJournal of Biological Chemistry, 2004
- The Thanatophoric Dysplasia Type II Mutation Hampers Complete Maturation of Fibroblast Growth Factor Receptor 3 (FGFR3), Which Activates Signal Transducer and Activator of Transcription 1 (STAT1) from the Endoplasmic ReticulumPublished by Elsevier ,2003
- Interaction of Fibroblast Growth Factor Receptor 3 and the Adapter Protein SH2-BPublished by Elsevier ,2002
- Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4Oncogene, 2000
- Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3Nature Genetics, 1996